F8 and hemophilia A: Reddy et al. [19] compared the efficacy and safety of hemophilia A gene therapy using a second generation Ad vector (E1,E2a,E3-deleted) and a HDAd, both containing the identical B-domain deleted human FVIII expression cassette.